ARGX Stock Overview
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €370.20 |
| 52 Week High | €486.30 |
| 52 Week Low | €303.50 |
| Beta | 0.37 |
| 1 Month Change | 4.16% |
| 3 Month Change | 0.76% |
| 1 Year Change | 2.21% |
| 3 Year Change | 67.51% |
| 5 Year Change | n/a |
| Change since IPO | 81.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARGX | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 1.7% | 0.03% | 1.6% |
| 1Y | 2.2% | -12.9% | 7.8% |
Return vs Industry: ARGX exceeded the Austrian Biotechs industry which returned -12.9% over the past year.
Return vs Market: ARGX underperformed the Austrian Market which returned 7.8% over the past year.
Price Volatility
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.0% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: ARGX has not had significant price volatility in the past 3 months.
Volatility Over Time: ARGX's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,148 | Tim Van Hauwermeiren | www.argenx.com |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
argenx SE Fundamentals Summary
| ARGX fundamental statistics | |
|---|---|
| Market cap | €20.66b |
| Earnings (TTM) | -€304.24m |
| Revenue (TTM) | €1.35b |
15.3x
P/S Ratio-67.9x
P/E RatioIs ARGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARGX income statement (TTM) | |
|---|---|
| Revenue | US$1.45b |
| Cost of Revenue | US$1.06b |
| Gross Profit | US$389.94m |
| Other Expenses | US$717.72m |
| Earnings | -US$327.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | -5.52 |
| Gross Margin | 26.87% |
| Net Profit Margin | -22.59% |
| Debt/Equity Ratio | 0.5% |
How did ARGX perform over the long term?
See historical performance and comparison